Kalle E Mattila, Leena Tiainen, Johanna Vikkula, Anna Kreutzman, Mia Engström-Risku, Kai Kysenius, Olivia Hölsä, Sari Hernesniemi, Päivikki Hemmilä, Anssi Pystynen, Siru Mäkelä
{"title":"Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study.","authors":"Kalle E Mattila, Leena Tiainen, Johanna Vikkula, Anna Kreutzman, Mia Engström-Risku, Kai Kysenius, Olivia Hölsä, Sari Hernesniemi, Päivikki Hemmilä, Anssi Pystynen, Siru Mäkelä","doi":"10.1080/14796694.2024.2403329","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> First-line (1L) immunotherapy has yielded superior overall survival (OS) in metastatic melanoma (MM) but some patients are ineligible for immunotherapy or need rapid response with 1L targeted therapy (TT).<b>Materials & methods:</b> Retrospective cohort study of real-world patients treated with 1L immunotherapy (144 <i>BRAF</i> wild type, 85 <i>BRAF</i>-mutated) or 1L TT (143 <i>BRAF</i>-mutated) for MM in Finland during 2014-2021.<b>Results:</b> Baseline brain metastases, liver metastases and elevated LDH were less common, 2-year OS rates were higher (60.3-63.5% vs. 33.8%) and more patients were alive without the next-line treatment (38.0-43.8% vs. 23.3%) in patients with 1L immunotherapy.<b>Conclusion:</b> Real-world patients with 1L immunotherapy for MM had favorable baseline characteristics and better treatment outcomes than observed in patients with 1L TT.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-15"},"PeriodicalIF":3.0000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2403329","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: First-line (1L) immunotherapy has yielded superior overall survival (OS) in metastatic melanoma (MM) but some patients are ineligible for immunotherapy or need rapid response with 1L targeted therapy (TT).Materials & methods: Retrospective cohort study of real-world patients treated with 1L immunotherapy (144 BRAF wild type, 85 BRAF-mutated) or 1L TT (143 BRAF-mutated) for MM in Finland during 2014-2021.Results: Baseline brain metastases, liver metastases and elevated LDH were less common, 2-year OS rates were higher (60.3-63.5% vs. 33.8%) and more patients were alive without the next-line treatment (38.0-43.8% vs. 23.3%) in patients with 1L immunotherapy.Conclusion: Real-world patients with 1L immunotherapy for MM had favorable baseline characteristics and better treatment outcomes than observed in patients with 1L TT.
目的：一线（1L）免疫疗法在转移性黑色素瘤（MM）中取得了较好的总生存率（OS），但有些患者不符合免疫疗法的条件，或者需要1L靶向疗法（TT）的快速反应：回顾性队列研究：2014-2021年间芬兰接受1L免疫疗法（144例BRAF野生型、85例BRAF突变型）或1L TT（143例BRAF突变型）治疗的MM患者的真实世界：结果：接受1L免疫治疗的患者中，基线脑转移、肝转移和LDH升高的情况较少，2年OS率较高（60.3-63.5% vs. 33.8%），更多患者在未接受下线治疗的情况下存活（38.0-43.8% vs. 23.3%）：结论：与1L TT患者相比，接受1L免疫治疗的MM患者具有良好的基线特征和更好的治疗效果。
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
